Literature DB >> 24219556

Activation of peroxisome proliferator-activated receptor gamma leads to upregulation of ESE-3 expression in human monocyte-derived dendritic cells.

F Sprater1, W Azeem, S Appel.   

Abstract

The transcription factor ESE-3 has been suggested to be involved in regulating the immunogenicity of human monocyte-derived dendritic cells (moDCs). While ESE-3 is not expressed in monocytes, it is upregulated during the differentiation of monocytes into dendritic cells (DCs) and highly expressed in immunogenic DCs while downregulated in tolerogenic DCs. Activation of peroxisome proliferator-activated receptor gamma (PPAR-γ) during DC development has been shown to result in a rather tolerogenic cell population. In this study, we identified eight PPAR-γ binding sites upstream of the ESE-3 gene. Activation of the PPAR-γ pathway with synthetic PPAR-γ ligands during moDC generation resulted in upregulation of ESE-3b expression on mRNA and protein level, phenotypic alterations and reduced capacity of the cells to stimulate allogeneic T cells. This could be inhibited by blocking the PPAR-γ pathway with specific antagonists. Our results suggest PPAR-γ to be involved in the regulation of ESE-3b expression during moDC development and that ESE-3 expression is not correlated with the immunogenicity of DCs.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24219556     DOI: 10.1111/sji.12126

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

Review 1.  Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses.

Authors:  Jun Li; Dawei Chen; Minhong Shen
Journal:  Front Med (Lausanne)       Date:  2022-03-23

2.  Dual Pro- and Anti-Inflammatory Features of Monocyte-Derived Dendritic Cells.

Authors:  Waqas Azeem; Ragnhild Maukon Bakke; Silke Appel; Anne Margrete Øyan; Karl-Henning Kalland
Journal:  Front Immunol       Date:  2020-03-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.